

Epizyme Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 18-Feb-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

 Phase 1 Clinical..... 11

 Discovery..... 22

[Return to Table of Contents](#)

Epizyme Inc

COMPANY OVERVIEW

Company Name	Epizyme Inc
Parent Company Name	Epizyme Inc
Website	http://www.epizyme.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	0
Number of Patents as Owner	11
Number of Patents as Third Party	3
Number of Deals	8
Key Indications	Cancer,Non-Hodgkin lymphoma,Acute lymphoblastic leukemia,Acute myelogenous leukemia,Sarcoma,Leukemia,Neurological disease,Diffuse large B-cell lymphoma,Follicle center lymphoma,Hematological neoplasm
Key Target-based Actions	Enhancer of zeste homolog 2 inhibitor,Histone H3 K79 methyltransferase inhibitor,Histone lysine methyltransferase inhibitor,Methyltransferase inhibitor,WHSC1 gene inhibitor,AMP activated protein kinase modulator,Beta adrenoceptor modulator,CLK4 protein kinase inhibitor,DNA polymerase inhibitor,Flt3 tyrosine kinase inhibitor,Glucocorticoid agonist,JMJD1A gene modulator,PCSK9 gene inhibitor,PDGF receptor alpha antagonist,PPAR alpha modulator,PPAR gamma coactivator 1-alpha modulator,Proprotein convertase PC9 inhibitor,Ros1 tyrosine kinase receptor inhibitor,Topoisomerase II inhibitor,TrkA receptor antagonist,TrkC receptor antagonist
Key Technologies	Small molecule therapeutic,Oral formulation,Systemic formulation unspecified,Drug screening,Drug combination,PCR based technology,Antibody,Condensational synthesis,Crystalline form,Gene transfer system,Genetic screening,Humanized antibody,Immunodetection,Immunofluorescence,Intravenous formulation,Liposome formulation,Oligonucleotide,Peptide,Salt

COMPANY PROFILE

SUMMARY

Epizyme Inc was established in 2007 and is focused on the development of drugs based on epigenetics.

FINANCIAL

In February 2014, the company announced an underwritten public offering of 4,192,679 shares. The offering was expected to contain 3,000,000 shares to be offered by Epizyme and 1,192,679 shares to be offered by existing stockholders. At that time, underwriters were expected to be granted a 30-day option to purchase up to 628,901 additional shares; later that month, the offering was priced at \$29.25 per share and the underwriters were a 30-day option to purchase up to 673,901 additional shares; later that month, the offering was closed.

In December 2013, the company was selected for addition to the NASDAQ Biotechnology Index, effective from December 23, 2013. At that time, the common stock was expected to be transferred to the NASDAQ Global Select Market, effective January 02, 2014.

In June 2013, the company was added to Russell 2000, Russell 3000 and Russell Global indexes.

In June 2013, Epizyme closed its initial public offering of 5,913,300 shares of its common stock at a public offering price of \$15.00 per share, before underwriting discounts, including 771,300 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the same price to cover over-allotments. At that time, the company expected net proceeds of approximately \$79.8 million. Later that month, the company raised net proceeds of \$82.5 million from the offering.

[Return to Table of Contents](#)



In April 2013, Epizyme filed a registration statement on Form S-1 with the US Securities and Exchange Commission relating to the proposed initial public offering of common stock; at that time, the company had not determine the number of shares and the price range for the offering. In May 2013, Epizyme priced its IPO of 5,142,000 common stock shares at \$15 per share. The underwriters were also granted a 30-day overallotment option to purchase up to an additional 771,300 common stock shares. The offering was expected to close on June 05, 2013 and at that time, the shares were scheduled to begin trading on the NASDAQ Global Market on May 31, 2013 under the ticker symbol 'EPZM'. In June 2013, the offering closed. The underwriters exercised in full the overallotment purchase option; the company expected to raise net proceeds of approximately \$79.8 million. In December 2013, NASDAQ reported that, Epizyme would be added to the NASDAQ Biotechnology Index, as a result of the annual re-ranking, which would become effective prior to market open on December 23, 2013.

In February 2008, the company raised \$14 million from a series A financing round.


In October 2009, the company raised \$32 million in a series B financing round. In December 2009, the company raised a further \$8 million from a second closing of the series B financing round, bringing the total raised to \$40 million.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	0	3
Hematological disease	2	0	2
Immune disorder	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	2
Discovery	1

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	1	0	1	0	2
Drug - Funding	2	0	0	0	2
Drug - Development/Commercialization License	3	0	0	0	3
Drug - Development Services	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Hematological disease	2	3
Neoplasm	2	3
Immune disorder	1	2

Trials by Phase

Phase	Ongoing	All
Phase 2	1	1
Phase 1	1	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	0	3	3
Endocrine disease	1	2	3
Gastrointestinal disease	0	2	2
Growth disorder	1	0	1
Hematological disease	6	0	6

[Return to Table of Contents](#)



Immune disorder	4	1	5
Musculoskeletal disease	0	1	1
Neoplasm	12	1	13
Ocular disease	0	1	1
Genetic disorder	1	0	1
Metabolic disorder	0	3	3
Neurological disease	5	1	6
Nutritional disorder	0	1	1
Respiratory disease	0	1	1
Inflammatory disease	0	1	1
Gynecology and obstetrics	1	0	1
Dermatological disease	2	1	3

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

EPZ-5676

EPZ-5676 SNAPSHOT

Drug Name	EPZ-5676
Key Synonyms	
Originator Company	Epizyme Inc
Active Companies	Celgene Corp;Epizyme Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Acute lymphoblastic leukemia;Acute myelogenous leukemia
Target-based Actions	Histone H3 K79 methyltransferase inhibitor
Other Actions	Anticancer;Synergist;Apoptosis stimulator
Technologies	Systemic formulation unspecified;Small molecule therapeutic
Last Change Date	30-Jan-2014

EPZ-5676 DEVELOPMENT PROFILE

SUMMARY

Epizyme and ex-US licensee Celgene are developing EPZ-5676d (EPZ-5676; structure shown), a small molecule S-adenosyl methionine competitive DOT1L inhibitor, for the potential treatment of acute leukemias in which the mixed lineage leukemia (MLL) gene is rearranged due to a chromosomal translocation (MLL-r), including MLL-r subtypes of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). In September 2012, a phase I trial was initiated ; in November 2013, interim data were reported and at that time, the expansion study was planned to be initiated in December 2013.

EPZ-5676 DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Celgene Corp	Acute lymphoblastic leukemia	World	Phase 1 Clinical	05-Sep-2012
Celgene Corp	Acute myelogenous leukemia	World	Phase 1 Clinical	05-Sep-2012
Epizyme Inc	Acute lymphoblastic leukemia	US	Phase 1 Clinical	05-Sep-2012
Epizyme Inc	Acute myelogenous leukemia	US	Phase 1 Clinical	05-Sep-2012

[Return to Table of Contents](#)



EPZ-5676 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
EPZ-5676	Research Code

EPZ-5676 DRUG NAMES

Names	Type
EPZ-5676d	Research Code
DOT1L inhibitors (mixed lineage leukemia), Epizyme/GlaxoSmithKline	
DOT1L inhibitors (leukemia), Epizyme/GSK	
EPZ-004777	Research Code
EPZ-5676	Research Code

EPZ-5676 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Leukemia											
0	0	0	0	0	0	1	1	0	0	1	1
Hematological neoplasm											
0	0	0	0	0	0	1	1	0	0	1	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	1	1	0	0	1	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

EPZ-5676 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Epizyme Inc	2	0	2	0	4
US Government	0	0	1	0	1
Abbott Laboratories	1	0	0	0	1
The Leukemia & Lymphoma Society	1	0	0	0	1
Celgene Corp	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1
Drug - Development/Commercialization License	1	0	1
Technology - Other Proprietary	1	0	1
Drug - Development Services	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Epizyme Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1
Product	1

[Return to Table of Contents](#)

E-7438

E-7438 SNAPSHOT

Drug Name	E-7438
Key Synonyms	
Originator Company	Epizyme Inc
Active Companies	Eisai Co Ltd;Epizyme Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Non-Hodgkin lymphoma;Sarcoma
Target-based Actions	Enhancer of zeste homolog 2 inhibitor;Histone lysine methyltransferase inhibitor
Other Actions	Anticancer;Synergist
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	09-Jan-2014

E-7438 DEVELOPMENT PROFILE

SUMMARY

Epizyme and licensee Eisai are developing E-7438 (EPZ-6438; structure shown), a lead from several small molecule EZH2 (enhancer of zeste homolog 2) inhibitors, including EPZ-5687 (EPZ-005687), from a program of histone methyltransferase inhibitors, for the potential oral treatment of cancers, including non-Hodgkin's lymphoma and breast cancer,. In June 2013, a phase I/II trial was initiated. In January 2014, Epizyme was planning to initiate two clinical POC studies, one in adult non-Hodgkin lymphoma patients and another in pediatric and young adult patients with synovial sarcomas and planning to develop the drug for the potential treatment of malignant rhabdoid tumors (MRT).

E-7438 DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Eisai Co Ltd	Non-Hodgkin lymphoma	France	Phase 1 Clinical	13-Jun-2013
Epizyme Inc	Non-Hodgkin lymphoma	France	Phase 1 Clinical	13-Jun-2013
Epizyme Inc	Sarcoma	US	Discovery	09-Jan-2014

E-7438 CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	5
	
Name	Type
EPZ-6438	Research Code
E-7438	Research Code

E-7438 DRUG NAMES

Names	Type
E-7438	Research Code
EPZ-6438	Research Code
EZH2 inhibitors (cancer), EpiZyme/Eisai	
EPZ-5687	Research Code
EPZ-005687	Research Code

E-7438 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Diffuse large B-cell lymphoma											
0	0	0	0	1	1	0	0	0	0	1	1
Advanced solid tumor											
0	0	0	0	1	1	0	0	0	0	1	1
Follicle center lymphoma											
0	0	0	0	1	1	0	0	0	0	1	1

[Return to Table of Contents](#)

Non-Hodgkin lymphoma											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	0	1	0	0	1	2


Phase Definitions

- Phase 3 Clinical**
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)
- Phase 2 Clinical**
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)
- Phase 1 Clinical**
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

E-7438 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Epizyme Inc	2	0	0	0	2
US Government	0	0	1	0	1
Eisai Co Ltd	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Epizyme Inc	4	0	4
Eisai Co Ltd	2	0	2
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product (derivative)	1
New use	1
Component of Combination	1
Tentative	1

[Return to Table of Contents](#)

histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline

histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline SNAPSHOT

Drug Name	histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline
Key Synonyms	
Originator Company	Epizyme Inc
Active Companies	GlaxoSmithKline plc;Epizyme Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	WHSC1 gene inhibitor;Methyltransferase inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	09-Jan-2014

histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline DEVELOPMENT PROFILE

SUMMARY

Epizyme and licensee GlaxoSmithKline (GSK) are investigating a program of small molecule histone methyltransferase (HMT) inhibitors, presumably including WHSC1 inhibitors, for the potential treatment of cancer and other diseases,. In October 2009, the company was planning proof-of-concept studies. In November 2010, development of the program was ongoing ; in January 2014, this was still the case.

histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Epizyme Inc	Cancer	US	Discovery	08-Oct-2009
GlaxoSmithKline plc	Cancer	UK	Discovery	10-Jan-2011


histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline DRUG NAMES

Names	Type
WHSC1 inhibitors (cancer), Epizyme/GSK	
histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Epizyme Inc	2	0	0	0	2
US Government	0	0	1	0	1
GlaxoSmithKline plc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

